Candel Therapeutics(NASDAQ) CADL

Candel helps cancer patients by using engineered viruses to fight tumors. These treatments train the body's immune system to attack cancer cells. The company focuses on hard-to-treat diseases like prostate and lung cancer.

Fighting Cancer with Viruses

• Aglatimagene: Engineered adenovirus treatment used with an inactive medicine called a prodrug to kill cancer cells and trigger immune responses.
• Linoserpaturev: Modified herpes virus designed to replicate inside and destroy brain tumor cells while sparing healthy tissue.
• enLIGHTEN Platform: Discovery system using advanced analytics to design new viral immunotherapy candidates for various solid tumors.

Strategic Moves and Clinical Progress

• Licensed several gene therapy assets from Periphagen in December 2019 to build the current clinical pipeline.
• Partnered with Mass General Brigham in September 2020 to license the linoserpaturev brain cancer program.
• Reported positive data from a Phase 3 clinical trial in localized prostate cancer in December 2024.
• Planned a regulatory filing for its lead prostate cancer treatment in the fourth quarter of 2026.

How Candel Stands Out

Viral immunotherapy uses modified viruses to trigger the body's natural defense system against cancer. Candel's treatments aim for an abscopal effect, where treating a single tumor helps the body fight distant, hidden cancer cells.

Tracking the Financial Progress

• Net income reached -$29.5 million in Q4 2025, deepening by 109.6% compared to the previous year.
• Operating income was -$15.8 million in Q4 2025, worsening by 93.5% from Q4 2024.
• Gross profit reached -$163,000 in Q4 2025, which improved by 33.5% year-over-year.
• Free cash flow was -$11 million in Q4 2025, deepening by 88.7% from the prior year.

The Bottom Line

Candel has evolved from a research-focused firm to a late-stage clinical developer. Its two distinct viral platforms allow the company to target a wide range of solid tumors.